

The latest on the Insulin Lispro shortage in 2026. Find out which formulations are affected, what the current pricing looks like, and how to find it in stock.
If you rely on Insulin Lispro to manage your diabetes, you've probably felt the impact of supply disruptions over the past couple of years. The shortages that began in 2024 have evolved — some formulations are back in steady supply, while others remain hard to find.
This article gives you the latest on the Insulin Lispro shortage situation in 2026, including which products are affected, how pricing has changed, and what you can do right now to make sure you don't run out of your medication.
The short answer: it depends on which formulation you use.
Here's the current picture:
The ASHP (American Society of Health-System Pharmacists) continues to track specific NDCs that are in limited supply. While the situation has improved significantly since the peak of the shortage in 2024, some patients — particularly in rural areas or those who use less common formulations — may still face challenges.
Several factors have contributed to the ongoing supply challenges:
When Eli Lilly cut Humalog's list price by 70% in 2023 and lowered generic Insulin Lispro vials to $25, demand surged. More patients gained access to affordable insulin — a great development — but manufacturers needed time to scale up production to meet the new volume.
Lilly's decision to discontinue the 3 mL vial presentations meant retooling production lines. These transitions don't happen overnight, and during the switchover, supply of certain products was reduced.
Insulin is a biologic product that requires specialized manufacturing facilities. Sanofi's reported shortages in Europe for their Insulin Lispro products suggest that global manufacturing capacity for rapid-acting insulin remains tight. This can create secondary effects on U.S. supply as manufacturers allocate limited capacity across markets.
For more background on why this medication has been difficult to locate, read our article on why Insulin Lispro is so hard to find.
The pricing landscape for Insulin Lispro has changed dramatically — mostly for the better. Here's what you can expect:
For detailed savings strategies, including coupons and patient assistance programs, see our complete guide on how to save money on Insulin Lispro in 2026.
Several developments in 2025 and 2026 have expanded options for patients who use rapid-acting insulin:
The availability of generic and biosimilar Insulin Lispro products continues to expand. Multiple manufacturers now offer authorized generic versions, increasing overall supply and price competition.
Eli Lilly's Lyumjev (insulin lispro-aabc) — the ultra-rapid version of Insulin Lispro — is increasingly available and covered by the same Lilly Insulin Value Program at $35/month. Some patients have found Lyumjev easier to locate during periods when standard Insulin Lispro is in short supply.
Tools like Medfinder make it easier than ever to compare pharmacy availability and find where your medication is in stock, reducing the guesswork that used to make shortages even more stressful.
If you're currently struggling to find Insulin Lispro, here are the most effective steps:
For a complete guide with more strategies, read our article on how to find Insulin Lispro in stock near you.
If Insulin Lispro simply isn't available in any form:
The Insulin Lispro shortage situation in 2026 is better than it was in 2024, but it's not fully resolved. Certain formulations have been discontinued, global supply remains tight for some products, and regional variations in availability persist.
The best thing you can do is stay informed, plan ahead (try to refill before you're down to your last pen or vial), and use tools like Medfinder to stay on top of local pharmacy stock.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.